Drugs / AR/101
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02839226 Comparator | Aug 2016 → Dec 2017 | ulcer disease | Arava Bio Tech Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR/101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02839226 ↗ |
| Route | Topical | “AR/101 will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician.” NCT02839226 ↗ |